Tier 1 — highest

Quercetin for the treatment of COVID-19 patients: A systematic review and meta-analysis

Huzaifa Ahmad Cheema, Aruba Sohail, Areej Fatima, Abia Shahid, Muhammad Shahzil, Mohammad Ebad Ur Rehman, Rehmat Ullah Awan, Sampath Chinnam, Abdulqadir J Nashwan
Reviews in medical virology 2023 33(2):e2427

Bibliography

PubMed
PMID 36779438
DOI
10.1002/rmv.2427
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignSystematic review and meta-analysis of randomized COVID-19 trials
ModelHuman evidence synthesis
Sample6 trials
InterventionQuercetin-containing regimens alongside contemporaneous care
DurationSearches through October 5, 2022
EndpointsEvents and survival

What the study showed, in plain terms

Published in 2023, this source examined immunity and respiratory health. Its evidence base was 6 trials. It evaluated Quercetin-containing regimens alongside contemporaneous care across Searches through October 5, 2022.

Hospital and intensive-care admission estimates favored quercetin, but all-cause mortality and failure to recover did not significantly improve.

Small trials, formulation differences, contemporaneous care, and overlapping or preliminary reports limit certainty and present-day applicability.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Immune Health, Colds and COVID-19. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Hospital and intensive-care admission estimates favored quercetin, but all-cause mortality and failure to recover did not significantly improve.
  • The recorded outcome domains were Events and survival.
  • This synthesis reuses the included study populations; it is not an additional randomized participant cohort.

What this study can and cannot tell us

  • Small trials, formulation differences, contemporaneous care, and overlapping or preliminary reports limit certainty and present-day applicability.
  • Pooled estimates depend on the included trials and may share participants with companion publications or other reviews. A statistically significant surrogate outcome does not establish disease prevention.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effect of quercetin supplementation on clinical outcomes in COVID-19 patients: A systematic review and meta-analysis
Somayeh Ziaei et al. · Food science & nutrition · 2023

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology